![Steven M. Fulda](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Mr. Fulda has served as one of our directors and a member of our audit committee since February 6, 2002.
Since 1989, Mr. Fulda has served as Managing Director of Fulda Business Planners.
Mr. Fulda has forty years of management and consulting experience including business strategy, planning, development and financing.
Since 1992, Mr. Fulda has been an Adjunct Professor of Entrepreneurship and Director of the Small Business Institute at Fairleigh Dickinson University.
Mr. Fulda holds a Master's Degree in Quantitative Business Analysis from New York University and a Master's Degree in Systems Engineering from Bell Laboratories' New York University Graduate Program.
Antiguos cargos conocidos de Steven M. Fulda.
Empresas | Cargo | Fin |
---|---|---|
Astralis Ltd.
![]() Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | Director/Miembro de la Junta | 30/12/2005 |
Formación de Steven M. Fulda.
New York University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Astralis Ltd.
![]() Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Steven M. Fulda